Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.

Baseline nausea, prior triptan use may influence oral diclofenac potassium solution efficacy in migraine

Audrey Abella
12 Jul 2017

Nausea at the time of dosing does not reduce the efficacy of diclofenac potassium for oral solution (DPOS) in acute migraine treatment, while prior triptan use predicted poor headache response compared with triptan-naïve patients, according to a study.

The pooled population from two double-blind trials included 1,272 patients aged 18–65 years (85 percent female) with at least a 1-year history of migraine attacks with or without aura who were randomized to receive 50 mg DPOS (n=628) or placebo (n=644). Participants were evaluated at 1, 2, and 8 hours postdosing to determine the intensity of migraine outcomes such as headache, photophobia, or phonophobia.

Sixty-two percent (n=783) of participants reported migraine-associated nausea at baseline, while 45 percent (n=570) had prior triptan use.

At 2 hours post-treatment, patients with baseline nausea who received DPOS had better responses compared with those receiving placebo in terms of headache relief (25 percent vs 9 percent; p<0.001) and absence of photophobia (45 percent vs 33 percent; p=0.002) or phonophobia (51 percent vs 36 percent; p<0.001). [Headache 2017;57:756-765]

Results were similar in participants without baseline nausea who demonstrated better relief on DPOS vs placebo in terms of headache relief (26 percent vs 13 percent; p<0.001) and absence of photophobia (54 percent vs 43 percent; p=0.009) or phonophobia (57 percent vs 44 percent; p=0.002).

The similar findings suggest that DPOS was effective regardless of presence of nausea at baseline, noted the researchers. “The rapid absorption profile [of DPOS] may enhance the effectiveness in patients with nausea,” they said.

Among patients with prior triptan use, DPOS-treated participants had better headache relief at 2 hours postdose compared with placebo-treated patients (20 percent vs 7 percent; p<0.001), though the efficacy appeared lower than that among triptan-naïve patients (30 percent vs 14 percent; p<0.001).

Prior triptan use did not predict relief of other measured parameters (ie, photophobia, phonophobia, or nausea) at 2 hours.

“These results suggest there may be a subset of patients who are more likely to be refractory to both triptans and diclofenac,” said the researchers, noting that this would require further investigation.

With previous evidence showing baseline nausea as a predictor of poor response to migraine treatment with triptans, it would be important to identify other migraine medications such as DPOS for effectively treating patients with poor triptan response, they added.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 6 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.